In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Arterial Hypertension (Management of)

ESC Clinical Practice Guidelines

Chronic Nursing Care
Pathophysiology and Mechanisms
Risk Factors and Prevention
Epidemiology, Prognosis, Outcome
Diagnostic Methods
Guidelines version available to download
Published in 2013
Reference European Heart Journal:34;2159–2219
Published in 2013
Reference Essential Messages from Arterial Hypertension
Published in 2013
Reference Summary Card on Arterial Hypertension
Published in 2013
Reference AH
Published in 2013
Reference Slides on Arterial Hypertension 2013
Published in 2013
Reference 36 CME Questions on Arterial Hypertension
Table of contents: Full Text (ESC Clinical Practice Guidelines)

2.Epidemiological aspects
    2.1. Relationship of blood pressure to CV & renal damage
    2.2.Definition & classification of hypertension
    2.3.Prevalence of hypertension
    2.4.Hypertension & total CV risk
3.Diagnostic evaluation
    3.1.Blood pressure measurement
    3.2.Medical therapy
    3.3.Physical examination
    3.4.Summary of recommendations on measurements, history & physical examination
    3.5.Laboratory investigations
    3.7.Searching for asymptomatic organ damage
    3.8.Searching for secondary forms of hypertension
4.Treatment approach
    4.1.Evidence favouring therapeutic reduction of high blood pressure
    4.2.When to initiate anihypertensive drug treatment
    4.3.Blood pressure treatment targets
5.Treatment strategies
    5.1.Lifestyle changes
    5.2.Pharmacological therapy
6.Treatment strategies in special conditions
    6.1.White-coat hypertension
    6.2.Masked hypertension
    6.4.Young adults
    6.6.Diabetes mellitus
    6.7.Metabolic syndrome
    6.8.Obstructive sleep apnoea
    6.9.Diabetic & non diabetic nephropthy
    6.10.Cerebrovascular disease
    6.11.Heart Disease
    6.12.Atherosclerosis, & PAD
    6.13.Sexual dysfunction
    6.14.Resistant hypertension
    6.15.Malignant hypertension
    6.16.Hypertensive emergencies & urgencies
    6.17.Perioperative management of hypertension
    6.18.Renovascular hypertension
    6.19.Primary aldosteronism
7.Treatment of associated risk factors
    7.1.Lipid lowering agents
    7.2.Antiplatelet therapy
    7.3.Treatment of hyperglycaemia
    7.4.Summary of recommendations on treatment of risks factors associated with hypertension
    8.1.Follow-up of hypertensive patients
    8.2.Follow-up of subjects with high normal blood pressure & white-coat hypertension
    8.3.Elevated blood pressure at control visits
    8.4.Continued search for asymptomatic organ damage
    8.5.Can antihypertensive medications be reduced or stopped?
9.Improvement of blood pressure control in hypertension
10.Hypertension disease management
    10.1.Team approach in disease management
    10.2.Mode of care delivery
    10.3.The role of information & communication technologies
11.Gaps in evidence & need for future trials


Task Force Members Disclosure Forms - 2007